Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 6,665 shares of the firm's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80. Following the completion of the transaction, the insider now directly owns 267,463 shares of the company's stock, valued at approximately $15,812,412.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.26, for a total transaction of $374,972.90.
- On Wednesday, September 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $47.56, for a total value of $316,987.40.
Apogee Therapeutics Price Performance
Apogee Therapeutics stock opened at $61.12 on Friday. The company's 50-day moving average is $54.25 and its 200-day moving average is $48.79. The firm has a market capitalization of $2.75 billion, a PE ratio of -29.53 and a beta of 2.93. Apogee Therapeutics, Inc. has a fifty-two week low of $14.19 and a fifty-two week high of $72.29.
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting analysts' consensus estimates of ($0.60). As a group, analysts expect that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock valued at $94,000 after purchasing an additional 285 shares during the last quarter. EntryPoint Capital LLC raised its position in shares of Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after purchasing an additional 617 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of Apogee Therapeutics during the 2nd quarter worth about $143,000. Kennedy Capital Management LLC bought a new stake in shares of Apogee Therapeutics during the 1st quarter worth about $212,000. Finally, Arizona State Retirement System boosted its holdings in shares of Apogee Therapeutics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock worth $236,000 after buying an additional 258 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, Wedbush reissued an "outperform" rating and set a $87.00 price target on shares of Apogee Therapeutics in a research report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics presently has a consensus rating of "Buy" and an average price target of $78.50.
Get Our Latest Stock Report on APGE
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
